MedPath

Increased Early Pain Relief by Adding Vertebroplasty to SBRT

Not Applicable
Recruiting
Conditions
Radiation Therapy
Pain
Spine Metastases
Interventions
Procedure: Vertebroplasty
Procedure: Stereotactic Body Radiation Therapy only
Registration Number
NCT05317026
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Brief Summary

The goal of treating metastases is to preserve stability and neurological function while reducing pain. The actual standard of care is stereotaxic body radiation therapy (SBRT) alone in non-surgical patients. The added value of vertebroplasty to SBRT is not well documented in the literature, nor whether performing vertebroplasty before radiotherapy treatment leads to a reduction in the rate of fractures and post-SBRT pain.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Histological evidence of cancer.
  • Spinal and vertebral bone metastases (T5 to L5) documented by imaging.
  • Pain related to metastases ≥ 4 on a numerical scale 0-10.
  • Karnofsky performance index > 60 (ecog 0-2)
  • Candidate for SBRT
  • Less than 3 consecutive levels reached.
  • Ability to complete follow-up questionnaires regarding pain, analgesics, and quality of life assessment.
  • Potentially unstable lesions according to the spinal instability neoplastic score (SINS) scale (> or = 7)
Exclusion Criteria
  • Pregnancy or breastfeeding.
  • Contraindications to MRI.
  • Histology: myeloma, lymphoma or plasmacytoma.
  • Radiotherapy prior to the level to be treated.
  • Previous surgery at the site to be treated.
  • Surgical indication:

spinal instability neoplastic score (SINS) > 13 or according to tumor board consensus.

Bilsky score > or = 2 Severe or progressive neurological signs (motor, incontinence).

  • Lesion too large for safe vertebroplasty.
  • High thoracic location not allowing safe visibility in fluoroscopy to perform vertebroplasty (T4 and above).
  • Non-reversible coagulation disorders.
  • Uncontrolled local or systemic infection.
  • Estimated survival of less than 6 months.
  • Inability or refusal to undergo SBRT treatment or vertebroplasty

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
V-SBRTVertebroplastyVertebroplasty followed by Stereotactic Body Radiation Therapy (SBRT)
SBRTStereotactic Body Radiation Therapy onlySBRT is the actual standard of care.
Primary Outcome Measures
NameTimeMethod
Pain change at 1 month1 month following the treatment

Visual Analogue Scale, from 0 to 10, 10 being the highest pain

Secondary Outcome Measures
NameTimeMethod
Pain change1 week, 1 month, 3 months and 6 months post treatment

Visual Analogue Scale, from 0 to 10, 10 being the highest pain

Change in level of physical, psychological and social functionsat 1 week, 1 month, 3 months and 6 months post treatment

EORTC Quality of life Questionnaire : QLQ-C30 (score between 0 and 100, highest numbers represents higher response and quality of life)

Change in performance for activities of daily livingat 1 week, 1 month, 3 months and 6 months post treatment

Karnofsky performance scale (score from 0 to 100, the lower the Karnofsky score, themore disable the patient is and need assistance)

Change in symptoms related to bone metastasisat 1 week, 1 month, 3 months and 6 months post treatment

QLQ-Bone metastases : BM22 questionnaire (All of the scales range in score from 0 to 100. A high score for the symptom scales represents a high level of symptomatology or problems, whilst a high score for the functional scales represents a high level of functioning)

Post-treatment fracture ratesat 3, 6, 12 and 24 months post treatment

evaluation by MRI +/- CT imaging

Trial Locations

Locations (2)

CHUM

🇨🇦

Montréal, Quebec, Canada

Véronique Freire

🇨🇦

Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath